Posted on December 31st 2010
In this study, the Nonverbal Medical Symptom Validity Test (NV-MSVT; Green, 2008) and the Test of Memory Malingering (TOMM; Tombaugh, 1996) were given to a consecutive series of outpatients undergoing disability assessment. No cases of moderate to severe traumatic brain injury (TBI) failed the easy NV-MSVT subtests or the TOMM. However, 26% of the mild TBI group failed the NV-MSVT and 10% failed the TOMM. More than 10% of the whole sample passed the TOMM but failed the NV-MSVT. Using profile analysis, the NV-MSVT has been shown to have a zero false-positive rate in three independent groups of patients with severe cognitive impairment arising from dementia. The more severe the actual cognitive impairment, the more likely it is that false positives for poor effort will occur. Therefore, usin...
Posted on December 31st 2010
Conclusions: This study demonstrated that simple clinical measurements of neurologic impairment (limb paresis, imbalance, other neurologic deficits) are of value in refining the prediction of long-term global outcome from TBI. These measurements may serve as markers of focal injury not captured by PTA duration, a severity marker weighted toward diffuse injury. (Source: PM and R)
Posted on December 31st 2010
In conclusion, a combined administration of progesterone and estrogen inhibited the decreasing effects of administration of progesterone and estrogen alone on water content and BBB disruption that mediated to change the proinflammatory cytokines.
PMID: 21186375 [PubMed - in process] (Source: Canadian Journal of Physiology and Pharmacology)
Posted on December 31st 2010
Authors: Moulder JE, Cohen EP, Fish BL
It is known that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can be used to mitigate radiation-induced renal injury. However, for a variety of reasons, these previous results are not directly applicable to the development of agents for the mitigation of injuries caused by terrorism-related radiation exposure. As part of an effort to develop an animal model that would fit the requirements of the U.S. Food and Drug Administration (FDA) "Animal Efficacy Rule", we designed new studies which used an FDA-approved ACEI (captopril) or an FDA-approved ARB (losartan, Cozaar®) started 10 days after a single total-body irradiation (TBI) at drug doses that are equivalent (on a g/m(2)/day basis) to the do...
Posted on December 29th 2010
The neurobehavioral sequelae of TBI consist of a spectrum of somatic, neurologic, and psychiatric symptoms. The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities. Specifically, the challenge is differentiating post-TBIârelated symptoms from preexisting or de novo psychiatric, neurologic, and/or systemic disorders. A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery. (Source: Neurologic Clinics)
Next Page »
Print This Post
|
Email This Post
